Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Proline homologation in melanostatin neuropeptide: discovery of potent modulators of the dopamine D2 receptors

  • Dias, Ivo E. Sampaio
  • Almeida, Hugo F. Costa
  • Correia, Xavier C.
  • Reis, Sara C. Silva
  • Costa, Vera M.
  • Brea Floriani, José Manuel
  • Loza García, María Isabel
  • Rodríguez Borges, José E.
  • García Mera, Xerardo
Melanostatin (MIF-1) is a naturally occurring neuropeptide acting as a positive allosteric modulator (PAM) of dopamine D2 receptors (D2R), underscoring its potential for therapeutic use in central nervous system disorders associated with dopaminergic dysregulation, including depression, drug addiction, restless legs syndrome, tardive dyskinesia, and Parkinson’s disease. In this work, a new series of MIF-1 analogs using l-pipecolic acid as an l-proline surrogate was synthesized and pharmacologically evaluated by functional assays at the D2R. In this series, methyl l-pipecolyl-l-leucylglycinate (9) was found to exhibit superior performance compared to MIF-1 by promoting a 4.1- and 4.2-fold increase of dopamine potency at 0.01 and 1 nM, respectively. In silico conformational studies demonstrate that 9 preferentially adopts a γ-turn, corroborating that neither the C-terminal carboxamide nor the postulated type II β-turn conformation is required for PAM activity. Toxicological assays in human dopaminergic SH-SY5Y neuronal cells show that this compound exhibits no significant toxicity up to 100 μM in the MTT reduction and neutral red uptake assays
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Exploring Biginelli-based scaffolds as A2B adenosine receptor antagonists: Unveiling novel structure-activity relationship trends, lead compounds, and potent colorectal anticancer agents

  • Prieto Díaz, Rubén
  • Fojo Carballo, Hugo
  • Majellaro, María
  • Tandarić, Tana
  • Azuaje Guerrero, Jhonny Alberto
  • Brea Floriani, José Manuel
  • Loza García, María Isabel
  • Barbazán García, Jorge
  • Salort, Glòria
  • Chotalia, Meera
  • Rodríguez Pampín, Iván
  • Mallo Abreu, Ana
  • Paleo Pillado, María Rita
  • García Mera, Xerardo
  • Ciruela, Francisco
  • Gutiérrez de Terán, Hugo
  • Sotelo Pérez, Eddy
Antagonists of the A2B adenosine receptor have recently emerged as targeted anticancer agents and immune checkpoint inhibitors within the realm of cancer immunotherapy. This study presents a comprehensive evaluation of novel Biginelli-assembled pyrimidine chemotypes, including mono-, bi-, and tricyclic derivatives, as A2BAR antagonists. We conducted a comprehensive examination of the adenosinergic profile (both binding and functional) of a large compound library consisting of 168 compounds. This approach unveiled original lead compounds and enabled the identification of novel structure-activity relationship (SAR) trends, which were supported by extensive computational studies, including quantum mechanical calculations and free energy perturbation (FEP) analysis. In total, 25 molecules showed attractive affinity (Ki < 100 nM) and outstanding selectivity for A2BAR. From these, five molecules corresponding to the new benzothiazole scaffold were below the Ki < 10 nM threshold, in addition to a novel dual A2A/A2B antagonist. The most potent compounds, and the dual antagonist, showed enantiospecific recognition in the A2BAR. Two A2BAR selective antagonists and the dual A2AAR/A2BAR antagonist reported in this study were assessed for their impact on colorectal cancer cell lines. The results revealed a significant and dose-dependent reduction in cell proliferation. Notably, the A2BAR antagonists exhibited remarkable specificity, as they did not impede the proliferation of non-tumoral cell lines. These findings support the efficacy and potential that A2BAR antagonists as valuable candidates for cancer therapy, but also that they can effectively complement strategies involving A2AAR antagonism in the context of immune checkpoint inhibition